Contents
For professionals · Chapter 1 of 12
The adult with recurrent inflammation
Start with the inflammatory pattern, its consequences and the dangerous alternatives. A recurrent fever is a problem to explain, not a diagnosis.
On this page
Recognize the pattern
Autoinflammatory conditions involve dysregulated innate immune pathways. Some are inherited; others arise without a simple germline explanation or develop through acquired somatic variants. “Autoinflammatory” does not mean that infection, malignancy or adaptive immune disease has already been excluded.
Reconstruct the earliest symptoms, including childhood events, rather than recording only the age at diagnosis. Document attack duration, interval health, objective temperatures, rash photographs, serositis, arthritis, oral or genital ulcers, eye symptoms, hearing changes and family history. Ask whether inflammation persists between attacks. An absent family history does not exclude genetic disease.
Establish what is happening now
During an informative episode, consider CBC with differential, CRP/ESR, renal and liver tests and urinalysis; ferritin is useful when systemic hyperinflammation is suspected. Repeat selected measures between attacks. Add cultures, imaging, tissue sampling and organ-specific tests according to the clinical problem, not a universal fever panel.
Review medications, travel and exposures, immune status, recurrent infections and constitutional symptoms. In an older adult, macrocytosis or otherwise unexplained cytopenias should change the differential. Persistent focal pain, a new murmur, weight loss or an abnormal examination requires its own investigation.
Use evidence without diagnostic shortcuts
High ferritin, a positive genetic panel or improvement with glucocorticoids is not independently diagnostic. Classification criteria support a structured assessment but do not replace exclusion of important mimics. A variant of uncertain significance is not a molecular diagnosis. Nonspecific autoantibodies can coexist and should not by themselves settle the mechanism.
Order genetic testing when the phenotype and potential clinical consequences justify it. Select germline or somatic testing deliberately, document assay coverage, and obtain genetics or an autoinflammation-center interpretation when results and phenotype diverge.
Decide urgency before naming the syndrome
Shock, altered consciousness, hypoxemia, severe new chest or abdominal pain, new neurologic deficits, bleeding, rapidly falling blood counts or evolving organ dysfunction require urgent hospital assessment. Infection can coexist with a flare. If MAS/HLH is suspected, investigation and treatment planning proceed together; do not wait for every criterion to accumulate.
The next clinical decision is often practical: which episode to sample, which organ to protect and who will reassess the patient. Record a working diagnosis and its uncertainty, the expected trajectory, and what would trigger reconsideration.
A practical differential at the first visit
| Pattern or clue | Competing explanation | Next discriminating step |
|---|---|---|
| Persistent fever, focal pain or a new murmur | Endocarditis, occult abscess, tuberculosis or another infection | Exposure and medication history; targeted cultures and imaging. Obtain cultures before antibiotics when feasible, without delaying sepsis treatment. |
| Weight loss, enlarging nodes, splenomegaly or cytopenias | Lymphoma, another hematologic malignancy, Castleman disease | Examine nodes and spleen; review smear and trends; arrange appropriate imaging and tissue diagnosis. A steroid response does not exclude lymphoma. |
| Fever after a new prescription or supplement | Drug fever or a systemic hypersensitivity reaction | Reconstruct the exposure timeline; assess rash, eosinophilia, liver and kidney injury. Stop a suspected culprit within a clinician-directed plan. |
| Regular mouth ulcers and infections with neutropenia | Cyclic neutropenia | Serial differential counts across symptomatic and well periods, with hematology input; one normal count is insufficient. |
| Reported episodes without corroborated inflammation | Measurement problems or a noninflammatory cause; rarely factitious illness | Verify the pattern respectfully. Do not infer deception from negative tests or unexplained symptoms. |
| Late onset, steroid dependence and macrocytosis | VEXAS or another clonal disorder | Evaluate common causes of macrocytosis and consider hematology with targeted somatic UBA1 testing. |
Start with CBC/differential, creatinine/eGFR, liver tests, CRP/ESR and urinalysis when indicated by the presentation. Add ferritin, triglycerides, fibrinogen and coagulation studies promptly when MAS/HLH is plausible. Blood cultures, HIV/TB testing, echocardiography, cross-sectional imaging and biopsy should answer a specific question; they are not an indiscriminate panel. ANA testing without a compatible connective-tissue phenotype can create incidental findings.
Capture an attack and its recovery
For a stable outpatient with a familiar, self-limited pattern, agree in advance how an attack will be documented. Standing laboratory orders can make sampling in the first 24–48 hours practical; specify which laboratory is open, who receives results and when the clinician will respond. This is a practical workflow, not a validated diagnostic time threshold. An emergency must not wait for the planned blood draw.
- Record start and end, measured temperature, symptoms, rash photographs, possible triggers, medicines taken and missed work. Keep the well intervals in the record too.
- Repeat selected inflammatory and renal measures when clinically well. Persistent CRP/SAA elevation changes the assessment even if the person feels better.
- Choose a follow-up date and an escalation threshold rather than leaving the patient to collect episodes indefinitely.
The patient attack diary is a printable discussion aid; detailed patient chapters require a free account.
Where Eurofever/PRINTO helps—and where it does not
The 2019 Eurofever/PRINTO criteria standardize classification of FMF, CAPS, TRAPS, MKD and PFAPA. Their prerequisites include inflammatory-marker elevation with flares, consideration of confounding infection, cancer, autoimmunity and other immune defects, and at least six months of recurrent activity. They should not be used to postpone needed treatment for six months or as a rule-out test for a newly ill adult.
Genotype-plus-phenotype and clinical-only approaches are distinct. For example, confirmatory MEFV findings plus a compatible feature are treated differently from a single pathogenic allele or uncertain result. Classification performance in a selected registry does not equal diagnostic accuracy in every adult fever clinic. Review the original criteria and variant definitions when using them; document the actual clinical basis of the diagnosis. See genetics and syndrome comparison.
Sources and further reading
- EULAR/ACR: diagnosis, management and monitoring of CAPS, TRAPS, MKD and DIRA (2021 points to consider; published 2022)
- ACR international guidance on VEXAS. Arthritis Rheumatol. 2026;78:509–522; online 2025
- Adult undifferentiated autoinflammatory disease and PFAPA: clinical cohort (2024)
- Histiocyte Society recommendations for HLH in adults (2019)
- Eurofever/PRINTO classification criteria for autoinflammatory recurrent fevers (2019)